OverviewSuggest Edit

EpiVax uses "immunoinformatics" computer modeling, gene sequencing and molecular immunology to develop new vaccines and to improve the immunogenicity profiles of new drugs. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. EpiVax won the prestigious AAPS Innovation award for its Tregitope technology. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). EpiVax’ 22 employees are “an incredibly creative group,” says De Groot, the company’s CEO and CSO. “We try to foster a balance between customer focus, Yankee frugality, and intellectual curiosity,” she says. “The critical components of our company’s innovations process are free thought, unencumbered imagination and an ability to connect the dots.” The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.”
HQProvidence, US
Employee Ratings3.9

Latest Updates

Employees (est.) (Nov 2020)32
Cybersecurity ratingAMore

Key People/Management at EpiVax

William Martin

William Martin

Clifford Grimm

Clifford Grimm

Leonard Moise

Leonard Moise

Scientific Director, Vaccine Research
Frances Terry

Frances Terry

Director of Analysis
Anne S. De Groot

Anne S. De Groot

Founder, CEO & CSO
Brian J. Roberts

Brian J. Roberts

Associate Scientific Director, Protein Therapeutics
Show more

EpiVax Office Locations

EpiVax has an office in Providence
Providence, US (HQ)
188 Valley St #424
Show all (1)

EpiVax Financials and Metrics

Summary Metrics

Founding Date


EpiVax total Funding

$3.2 m

EpiVax latest funding size

$55 k

Time since last funding

8 years ago

EpiVax investors

EpiVax's latest funding round in November 2012 was reported to be $55 k. In total, EpiVax has raised $3.2 m
Show all financial metrics

EpiVax Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

EpiVax Online and Social Media Presence

Embed Graph

EpiVax News and Updates

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

PROVIDENCE, R.I., Oct. 22, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug...

Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine

BILTHOVEN, Netherlands and PROVIDENCE, Rhode Island, June 2, 2020 /PRNewswire/ -- Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and EpiVax, a biotechnology company...

EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

PROVIDENCE, R.I., April 7, 2020 /PRNewswire/ -- EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) into clinical trials in 6 months. Today, EpiVax announces its partnership with GAIA Vaccine Foundation...

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

PROVIDENCE, R.I., Nov. 6, 2019 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in...

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

NEW YORK, March 25, 2019 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on...

EpiVax Oncology Appoints Dominique Bridon as Chief Technology Officer and Dan Adams to the Board of Directors

NEW YORK and PROVIDENCE, R.I., Oct. 22, 2018 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, is pleased to announce the appointment of Dominique Bridon as Chief Technology Officer and the appointment of Dan Adams to the Board of Directors, both effective...
Show more

EpiVax Blogs

Antibody Industrial Symposium (AIS) 2020 Virtual

The post Antibody Industrial Symposium (AIS) 2020 Virtual appeared first on EpiVax, Inc. - Informatics and Immunology.

American Association of Pharmaceutical Scientists (AAPS) – PharmSci360

EpiVax is proud to have three of our Director and Senior level scientists representing our work at the 2020 AAPS PharmSci 360 Meetings. There are several opportunities to catch up with them over the next two weeks including the following rapid fire talks: Brian Roberts, PhD Rapid Fire: https://www.eventscribe.com/2020/PharmSci360/index.asp?presTarget=1414336…

November Newsletter: The What If Machine sees into the Future

The What If Machine, as applied to Immunogenicity Well Hello Again! Our PANDA program is back in the news. Having just completed validation studies on Salmon Calcitonin and Teriparatide,  we’re back in the business of predicting the future with the What If Machine! More info here and on our website.…

September newsletter – Generic PANDA monium!

Generic PANDAmonium I have been hanging out with an old dog – eight year old Jack, during the COVID lockdown. If you are a dog during COVID-19, long walks, lots of snuggles on the couch during Zoom meetings, what’s not to like? Hence the theme of my latest talk that is now posted on line – “New […] …

PANDA: Immunogenicity of Peptide Drugs Webinar with Live Q&A

Join us for a live Webinar featuring PANDA: Immunogenicity of Peptide Drugs You can expect an email ~24 hours before the start of the webinar that will contain the link that will allow you to join. The post PANDA: Immunogenicity of Peptide Drugs Webinar with Live Q&amp;A appeared first on EpiVax, In…

TIDES: Oligonucleotide and Peptide Therapeutics Virtual

EpiVax continues to “meet” with global clients despite pandemic restrictions through virtual meetings and conferences such as TIDES: Oligonucleotide and Peptide Therapeutics Virtual! In addition to participating in a Live Panel Discussion on FDA Draft Guidance on ANDA Filings for Peptides, our CEO/C…
Show more

EpiVax Frequently Asked Questions

  • When was EpiVax founded?

    EpiVax was founded in 1998.

  • Who are EpiVax key executives?

    EpiVax's key executives are William Martin, Clifford Grimm and Leonard Moise.

  • How many employees does EpiVax have?

    EpiVax has 33 employees.

  • Who are EpiVax competitors?

    Competitors of EpiVax include Transgene, Magenta Therapeutics and Synthace.

  • Where is EpiVax headquarters?

    EpiVax headquarters is located at 188 Valley St #424, Providence.

  • Where are EpiVax offices?

    EpiVax has an office in Providence.

  • How many offices does EpiVax have?

    EpiVax has 1 office.